Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.

Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilization, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.

Abstract: The present invention relates to compositions comprising a therapeutically effective amount of miRNAs, their use for the treatment of medical conditions benefiting from being treated with these compositions, as well as methods for the preparation of compositions comprising miRNAs.

Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.

Abstract: The present invention relates to compositions comprising a therapeutically effective amount of miRNAs, their use for the treatment of medical conditions benefiting from being treated with these compositions, as well as methods for the preparation of compositions comprising miRNAs.

Abstract: The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases and disorders associated with inflammation and/or undesirable activation of the immune system, such as paradentosis, abortus habitualis, colitis ulcerosa, polymyalgia rheumatica, whiplash-associated disorders, endometriosis, adeomyosis and unexplained infertility.

Abstract: The present invention relates to a method and a system for producing a mammalian pre-embryo and a stem cell having a better quality than prior art methods. The system comprises means for obtaining a mammalian oocyte, and means for obtaining a mammalian spermatozoa, and an apparatus having at least two separate air-tight chambers, for which the oxygen tension of one chamber may be changed independent of the oxygen tension of the other chamber, said at least two separate air-tight chambers constitute a main chamber and at least one residence chamber.

Abstract: The present invention relates to a method and a system for producing a mammalian pre-embryo and a stem cell having a better quality than prior art methods. The system comprises means for obtaining a mammalian oocyte, and means for obtaining a mammalian spermatozoa, and an apparatus having at least two separate air-tight chambers, for which the oxygen tension of one chamber may be changed independent of the oxygen tension of the other chamber, said at least two separate air-tight chambers constitute a main chamber and at least one residence chamber.

Abstract: The present invention relates to a method and a system for producing a mammalian pre-embryo and a stem cell having a better quality than prior art methods. The system comprises means for obtaining a mammalian oocyte, and means for obtaining a mammalian spermatozoa, and an apparatus having at least two separate air-tight chambers, for which the oxygen tension of one chamber may be changed independent of the oxygen tension of the other chamber, said at least two separate air-tight chambers constitute a main chamber and at least one residence chamber.

Abstract: The present invention relates to a method and a system for producing a mammalian pre-embryo and a stem cell having a better quality than prior art methods. The system comprises means for obtaining a mammalian oocyte, and means for obtaining a mammalian spermatozoa, and an apparatus having at least two separate air-tight chambers, for which the oxygen tension of one chamber may be changed independent of the oxygen tension of the other chamber, said at least two separate air-tight chambers constitute a main chamber and at least one residence chamber.

Abstract: The present invention relates to an assay for at least one predictive marker in a sample from a mammal wherein a specific reaction for at least one predictive marker indicates when non-fertilizable ova capable of in vitro maturation (IVM) and subsequent in vitro fertilization (IVF) are present in the mammal. This is particularly useful in the determination of when non-fertilizable ova, if aspirated, after in vitro maturation to MF-II will be capable of fertilization and pregnancy after implantation into the female mammal. The assay is based on a sample selected from the group consisting of body secrete, sputum, blood, urine, uterus secretes and cells.

Abstract: The present invention relates to a method for in vitro maturation of a human gamete by culturing an immature human gamete in a chemically defined cell culture medium. The human gamete can be a spermatocyte or an oocyte. The maturation end point is metaII. The advantage of the described medium is a synchronised cumulus-, cytoand nuclear maturation completed within a period of 20 to 30 hours. The medium should preferably contain ATA (Aurin Tri Carboxylicacid) as an anti-apototic agent. The medium should preferably not contain BSA, HSA or other directly serum derived products or substances.

Abstract: The present invention relates to a method for in vitro maturation of a human oocyte by culturing an immature human oocyte in a cell culture medium for 10-30 hours. The maturation end point is metaphase II.